Do statins play a role in the early management of the acute coronary syndrome?

European Heart Journal, Supplement

Volumn 6, Issue A, 2004, Pages

  Sacks, Frank M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute coronary syndrome; Angina; Myocardial infarction; Statins

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ANGINA PECTORIS; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROTIC PLAQUE; ATHEROSCLEROTIC PLAQUE STABILITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; VASCULAR ENDOTHELIUM;

EID: 1642379307     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehjsup.2004.01.008     Document Type: Conference Paper

References (36)

1. Paradiso-Hardy FL, Gordon WL, Jackevicius CA et al. The importance of in-hospital statin therapy for patients with acute coronary syndromes. Pharmacotherapy 2003;23:506-13.
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
3. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996;335:1001-9.
4. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
5. Aronow HD, Topol EJ, Roe MT et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001;357:1063-8.
6. Stenestrand U, Wallentin L. Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001;285:430-6.
7. Newby LK, Kristinsson A, Bhapkar MV et al. SYMPHONY and 2nd SYMPHONY Investigators. Sibrafiban vs Aspirin to Yield Maximun Protection From Ischemic Heart Events Post-acute Coronary Syndromes. Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA 2002;287:3087-95.
8. Heeschen C, Hamm CW, Laufs U et al. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002;105:1446-52.
9. Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: a randomized controlled trial. JAMA 2001; 285:1711-8.
10. Sacks FM. Lipid-lowering therapy in acute coronary syndromes. JAMA 2001;285:1758-60.
11. Wright RS, Murphy JG, Bybee KA et al. Statin Lipid-lowering therapy for acute myocardial infarction and unstable angina: efficacy and mechanism of benefit. Mayo Clin Proc 2002;77:1085-92.
12. Bybee KA, Wright RS, Powell BD et al. Differential benefit from treatment with a statin agent at hospital discharge in non-ST elevation MI compared with ST elevation MI. Circulation 2000;102(Suppl 2):II-614.
13. Bybee KA, Wright RS, Williams BA et al. Effect of concomitant or very early statin administration on in-hospital mortality and reinfarction in patients with acute myocardial infarction. Am J Cardiol 2001;87:771-4.
14. Giugliano RP, Antman EM, Thompson SL et al. Lipid lowering drug therapy initiated during hospitalization for acute MI is associated with lower postdischarge 1-year mortality. J Am Coll Cardiol 2001;37(Suppl A):316A.
15. Cannon CP, McCabe CH, Bentley J et al. Early statin therapy is associated with markedly lower mortality in patients with acute coronary syndromes: observations from OPUS-TIMI 16. J Am Coll Cardiol 2001;37(Suppl A):334A.
16. Arntz HR, Agrawal R, Wunderlich W et al. Beneficial effects of pravastatin (±colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). Am J Cardiol 2000;86:1293-8.
17. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
18. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002;40:1366-74.
19. Jones PH, Davidson MH, Stein EA et al. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003;92:152-60.
20. Cannon CP, McCabe CH, Belder R et al. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol 2002;89:860-1.
21. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002;110:285-8.
22. Lefer AM, Campbell B, Shin YK et al. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 1999;100:178-84.
23. Stalker TJ, Lefer AM, Scalia R. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharmacol 2001;133:406-12.
24. Laufs U. Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol 2003;58:719-31.
25. Llevadot J, Murasawa S, Kureishi Y et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 2001;108:399-405.
26. Walter DH, Rittig K, Bahlmann FH et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002;105:3017-24.
27. Werner N, Priller J, Laufs U et al. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol 2002;22:1567-72.
28. Albert MA, Danielson E, Rifai N et al. PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70.
29. Ridker PM, Rifai N, Clearfield M et al. Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-65.
30. Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 2003;41(4 Suppl S):37S-42S.
31. Correia LC, Sposito AC, Lima JC et al. Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris and non-Q-wave acute myocardial infarction. Am J Cardiol 2003;92:298-301.
32. Libby P, Aikawa M. Mechanisms of plaque stabilization with statins. Am J Cardiol 2003;91:4B-8B.
33. Crisby M, Nordin-Fredriksson G, Shah PK et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103:926-33.
34. Fukumoto Y, Libby P, Rabkin E et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation 2001;103:993-9.
35. Semb AG, van Wissen S, Ueland T et al. Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: down-regulatory effect of statin therapy. J Am Coll Cardiol 2003;41:275-9.
36. Node K, Fujita M, Kitakaze M et al. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003;108:839-43.